OX40L gene polymorphism and breast cancer in Iranian population by Vakil Monfared, R. & Mashayekhi, F.
132 Experimental Oncology 40, 132–135, 2018 (June)
OX40L GENE POLYMORPHISM AND BREAST CANCER  
IN IRANIAN POPULATION
R. Vakil Monfared, F. Mashayekhi*
Department of Biology, Faculty of Sciences, University of Guilan, Rasht 4193833697, Iran
Background and Aim: The immune system plays an important role in the breast cancer development. OX40L (also known as TNFSF4), 
a membrane protein, which is a member of the tumor necrosis factor super family binds to its receptor OX40 and this co-stimulation 
has a crucial role in T cell proliferation, survival and cytokine release. Previous studies have shown that OX40L is associated with 
cancer. Due to the importance of the T cells in antitumor activities of OX40L we studied the association of rs3850641 (A→G) 
polymorphism of OX40L gene with the breast cancer. Materials and Methods: The study included 123 women with breast cancer 
and 126 healthy volunteers with no signs of cancer. Genomic DNA was extracted from blood leucocytes. Genotype and allele fre-
quencies were determined in patients and control cases with the method of polymerase chain reaction-restriction fragment length 
polymorphism and the statistical analysis was performed by Med Calc. Results: The prevalence of genotype frequencies of AA/
AG/GG were 60.9%, 30.08% and 8.9% in patients with breast cancer cases and 74.6%, 18.25% and 7.14% in healthy volunteers 
while the A and G allelic frequency was 76.01 and 23.98% in patients and 83.73 and 16.26% in healthy controls, respectively. 
Statistical analysis has shown signiﬁcant difference from the comparison of genotype (p = 0.03). Conclusion: It is concluded that 
the rs3850641 SNP is significantly associated with the breast cancer susceptibility in Iranian population. However, further studies 
in larger populations including other genetic and environmental factors are required to achieve conclusion.
Key Words: OX40L, gene polymorphism, breast cancer, PCR-RFLP.
Breast cancer is the most common invasive ma-
lignancy among women worldwide with an incidence 
reaching more than one million new cases [1]. Stud-
ies have indicated that the mean age of patients with 
breast cancer in Iran is approximately 10 years younger 
than in western countries [2]. Genetics and envi-
ronmental factors have been shown to be important 
in breast cancer initiation and promotion. Many genes 
have been shown to have important roles in breast can-
cer onset, invasion, metastasis and prognosis. OX40L 
which is also known as TNFSF4 and gp34 is a member 
of the tumor necrosis factor (TNF) super family and 
was first identified as gp34 on HTLV-I transformed 
cells [3]. OX40L is a type II glycoprotein which 
is located on the human chromosome 1 [4]. OX40L 
is expressed on activated antigen presenting cells like 
B cells [5], dendritic cells [6] and macrophages [7] 
as well as natural killer cells (NK cells) [8], Langerhans 
cells [9], airway smooth muscle cells [10] and vascular 
endothelial cells [11]. OX40L is also expressed on the 
surface of activated T cells which enhances further 
T cell responses [12]. Its receptor OX40 is expressed 
on activated T cells and its ligation to OX40L promotes 
pathways which regulate the T cell proliferation, effec-
tive activation, survival and cytokine release from the 
T cells [13]. Unlike OX40 expressing T cells, OX40L ex-
pressing cells are only found in inflammatory sites and 
only those T cells which migrate to inflammatory sites 
can receive the co-stimulatory effect of OX40L [7]. 
This prevents the widespread activation of OX40 on ac-
tivated T cells [14]. OX40 stimulation results in IL-2R 
expression and IL-2 production which affects the T cell 
survival and effector differentiation through down-
stream molecules like nuclear factor kappa-B (NF-κB) 
and survivin [15]. The ligation of OX40 leads to the 
activation of the NF-κB by TRAF-2 induction which 
promotes the transcription of the target genes [16], 
and the activation of PI-3K and protein kinase B (also 
known as AKT activation) [17]. The activation of Akt 
results in the expressing anti-apoptotic molecules like 
Bcl-2 and Bcl-xl [18].
The anti-apoptotic protein survivin which is acti-
vated by an AKT/PKB-dependent activation increases 
the survival of the activated T cell, which leads to the 
increase of T cell clonal expansion [19]. OX40 stimu-
lation leads to enhanced CD8 T cell differentiation 
against soluble or tumor associated antigen, which 
results in the increased expression of CD25 and 
granzyme B expression and enhanced cytolytic activ-
ity [20] and also the accumulation of CD8 at the tumor 
site [21].
It has been shown that OX40L polymorphisms are 
associated with diseases like systemic lupus erythe-
matosus (SLE) [22] and systemic sclerosis [23]. Some 
studies have shown that OX40L fusion protein inhibited 
the growth of mouse 4T1 breast tumor model [24]. 
The OX40L rs3850641SNP is located at intron 1 of the 
OX40L. Variants in the intron of a gene may influence 
its expression and regulate its function. In this study 
we aimed to determine the association of the OX40L 
polymorphism with breast cancer in Iran.
MATERIALS AND METHODS
Blood samples were collected from a total 
of 123 patients with sporadic breast cancer and 
126 healthy blood donors as control cases with 
no signs of any cancer. The study has been approved 
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by the appropriate ethics committee and have been 
performed in accordance with the ethical standards 
laid down in the 1964 Declaration of Helsinki and its 
later amendments. All persons gave their informed 
consent prior to their inclusion in the study.
We extracted the genomic DNA from blood cells 
by using Gpp Solution DNA extraction kit (Genpajo-
ohan, Iran), Chloroform, 90% and 70% ethanol and 
NaCl. The target genes OX40L, with a 769 base pair 
length, was amplified by using forward and reverse 
primers (Table 1) (Generay, China) by polymerase 
chain reaction (PCR). The PCR mixture contained 
10 µl Master mix, 1 µl of each primer, 5 µl template 
DNA and 3 µl deionized water. Amplification was 
performed as followed: denaturation for 5 min 
at 95 °C and 35 cycles with the program 95 °C in 45 s, 
annealing temperature 55 °C for 45 s, 72 °C for 45 s and 
finally 72 °C for 5 min to ensure the product extension.
Table 1. Forward and reverse primer designation used in amplification
Primer designation Primer sequences Length
Forward 5´-TCTTATGCCAAAAGTGTTGAGT-3´ 22bp
Reverse 5´-TAGCTCAACAAAGGAACACGA-3´ 21bp
The PCR products were electrophoresed on 2% aga-
rose gel and visualized by UV light. After being sure 
of having PCR products the products were digested 
by HpyCH4III which cutes the DNA in the ACN*GT re-
striction site and the result is DNA fragments with the 
sizes of 769, 521, and 248 base pairs. The products 
were electrophoresed on 2% agarose gel (Figure).
Figure. Agarose gel electrophoresis after the digestion of the 
DNA of the patient group by HpyCH4III. A 769bp segment 
represents A/A homozygosis (A) while 769, 521, and 248 base 
pairs represent A/G Heterozygosis (B). Segments sized 521 and 
248 represent G/G mutant homozygosis
Statistical analysis. The statistical analysis was 
performed by MedCalc chi-square test (version 14.8.1) 
to make a comparison between genotypes and al-
leles. We used Hardy — Weinberg equilibrium (HWE) 
to evaluate deviation between observed and expected 
frequencies. A value of p < 0.05 was considered sta-
tistically signiﬁcant.
RESULTS
The study included 123 controls and 126 patients 
with breast cancer. The patients ranged in the age 
group from 20 to 80 years old, and the healthy controls 
aged from 20 to 70 years old. The PCR product had 
a 769 base pair length and the details of enzyme diges-
tion are shown in Table 2. The Hardy — Weinberg analy-
sis is shown in Table 3. Distribution of OX40L geno types 
was incompatible with HWE for control group but not 
for breast cancer patients (p = 0.00082 and p = 0.07, 
respectively). Deviation from HWE can be caused 
by some reasons such as small number of subjects 
or random genetic drift. The allele and genotypes fre-
quencies of the studied genetic variants in breast can-
cer cases and healthy subjects are shown in Table 4. 
The genotype frequencies of AA/AG/GG were 60.9%, 
30.08% and 8.9% in breast cancer cases and 74.6%, 
18.25% and 7.14% in healthy volunteers.
Table 2. Restriction fragment length polymorphism data of the restriction 
site of HpyCH4III and the sizes of DNA fragments after digestion by this 
enzyme
Enzyme HpyCH4III
Restriction site 5´…ACNGT…3´
3´…TGNCA…5´
Size of DNA segments  
after digestion
T/T genotype 769 bp
T/C genotype 769,521,248 bp
C/C genotype 521,248 bp
Table 3. Hardy — Weinberg analysis
Subjects Genotypes Alleles pAA AG GG A G
Controls, n (%) 94 (75) 23 (18) 9 (7) 211 (84) 41 (16) 0.00082
Patients, n (%) 75 (61) 37 (30) 11 (9) 187 (76) 59 (24) 0.07
Table 4. Genotype and allele distributions of rs3850641 polymorphism
Genetic
models
Geno-
types
Controls,
n (%)
Patients,
n (%) OR (95% CI) p
Codominant AA
AG
GG
94 (74.6)
23 (18.2)
9 (7.1)
75 (61.0)
37 (30.1)
11 (8.9)
1.00
2.02 (1.10–3.68)
1.53 (0.60–3.89)
0.061
Dominant AA
AG-GG
94 (74.6)
32 (25.4)
75 (61.0)
48 (39.0)
1.00
1.88 (1.09–3.23) 0.021
Recessive AA-AG
GG
117 (92.9)
9 (7.1)
112 (91.1)
11 (8.9)
1.00
1.28 (0.51–3.20) 0.6
Overdominant AA-GG
AG
103 (81.8)
23 (18.2)
86 (69.9)
37 (30.1)
1.00
1.93 (1.06–3.49) 0.029
Log-additive – – – 1.48 (0.99–2.21) 0.54
Alleles A
G
211 (84.0)
41 (16.0)
187 (76.0)
59 (24.0)
1.00
1.62 (1.04–2.53) 0.03
The AG and GG genotypes of the polymorphism 
were seen in 48 patients with breast cancer (39.0%) 
and 32 controls (25.4%) (dominant model: OR = 1.88; 
95% CI 1.09–3.23; p = 0.021). The association was also 
significant when analyzing the AG genotype in over-
dominant model (OR = 1.93; 95% CI 1.06–3.49; p = 
0.029). The A allele frequency was 76.01% in patients 
and 83.73% in control groups. The prevalence of G al-
lele was 23.98% in patients and 16.26% in the control 
group. The results show that there is a signiﬁcant 
difference in the genotype and allele frequencies be-
tween two groups (p = 0.04 and p = 0.03, respectively) 
(see Table 4).
DISCUSSION
The objective of this study was to examine the rela-
tionship between OX40L rs3850641 polymorphism and 
breast cancer susceptibility in Iran. Result reveal that 
rs3850641 G allele is associated with a significantly 
higher risk of breast cancer.
Breast cancer is the most common invasive malig-
nancy type worldwide. It is estimated that more than 
one million women are diagnosed with breast cancer 
and 450,000 cases die annually by this disease [1]. 
OX40L, a type 2 membrane protein, is a member of the 
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TNF superfamily [5]. OX40L is expressed by acti-
vated B cells, vessel endothelial cells, macrophages, 
dendritic cells and certain activated T cells. This 
generates co-stimulatory signals by interacting with 
TNFRSF4 on activated T lymphocytes and enhances 
the proliferation and differentiation of T lympho-
cytes and the development and survival of memory 
T cells [25]. A study by Zaini et al. [26] has shown 
that TNF-α-stimulated dendritic cells maturation 
in mice was accompanied by increased expression 
of OX40 ligand (OX40L), the lack of which resulted 
in an inability of mature dendritic cells to generate 
cellular antitumor immunity. Furthermore, intratumoral 
administration of dendritic cells modified to express 
OX40L suppressed tumor growth through the genera-
tion of tumor-specific cytolytic T cell responses, which 
were mediated by CD4 T cells and NK T cells. In the 
tumors treated with OX40L-expressing dendritic cells, 
the NK T cell population significantly increased and 
exhibited a substantial level of IFN-γ production es-
sential for antitumor immunity. These results indicate 
that the OX40L expression on dendritic cells is crucial 
in the development of antitumor immunity, possibly 
by coupling innate to adaptive immunity [26].
The proliferation of naive CD8 T cells or previously 
activated CD8+ T cells were suppressed by regulatory 
T cells (Tregs), though not to the same extent as CD4+ 
T cells. Tregs suppressed the proliferation of naive 
CD4+, naive CD8+ T and CD25− T cells after TCR trig-
gering, in contrast, OX40 co-stimulated Tregs that 
reduced Foxp3 expression reversed the suppressive 
function [27].
Studies have shown that OX40L polymorphisms 
are associated with SLE [22]. Another study has 
shown the association of the OX40L polymorphism 
in systemic sclerosis [23]. Polymorphisms of OX40L 
are also associated with arthrosclerosis [28]. Other 
studies suggested that OX40L polymorphism was as-
sociated with myocardial infarction [29]. Fu et al. [30] 
conducted a meta-analysis with 9 articles to assess 
the relationship between rs3850641 genetic poly-
morphisms and coronary heart disease. They found 
that rs3850641 was not associated with increased risk 
of coronary heart disease [30]. In agreement with this 
result, Lu et al. [31] reported that there is no main ef-
fect of OX40L gene polymorphism on cerebrovascular 
and cardiovascular diseases risk. So far, only one 
case-control study of breast cancer and OX40L gene 
polymorphism has been carried out with 557 cases 
and 580 controls [32]. They found significant associa-
tion between rs3850641 and breast cancer risk under 
the additive and dominant models (p = 0.01042 and 
p = 0.01942, respectively). Moreover, rs3850641G al-
lele could increase the susceptibility to breast cancer 
(p = 0.009662).
It is found that in a mouse model of allergic asthma 
basophiles highly expressed OX40 ligand (OX40L) af-
ter activation. The results reveal a critical role of OX40L 
presented by the activated basophiles to initiate 
Th2 responses in an allergic asthma model, implicat-
ing OX40-OX40L signaling as a potential therapeutic 
target in the treatment of allergic airway inflamma-
tion [12]. Blocking OX40-OX40L interaction has been 
considered an approach to the treatment of various 
diseases in which T cells play a critical role. In animal 
models, OX40L blockade in vivo has been shown 
to weaken harmful diseases in many inflammatory 
and autoimmune models like allergic asthma, colitis, 
diabetes, arthritis, atherosclerosis and allograft rejec-
tion. Evidences showed that inflammatory responses 
play a crucial role at different stages of tumor develop-
ment and contributes to the initiation and progression 
of cancer [33].
It is concluded that the rs3850641 polymorphism 
is associated with the susceptibility of breast cancer 
in Iran. It is necessary to confirm this result with larger 
sample size in multiethnic groups in the future.
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